Eterna Therapeutics (NASDAQ:ERNA) has announced the appointment of Elena Ratner, MD, MBA, to its board of directors.
The company states that Dr. Ratner will spearhead the strategic direction of Eterna’s efforts to combat ovarian cancer, leveraging her extensive expertise in obstetrics, gynecology, and reproductive sciences. Dr. Ratner is a professor in the department of obstetrics, gynecology, and reproductive sciences at Yale University School of Medicine.
“I’m excited to join Eterna and contribute my passion for fighting ovarian cancer to the company’s inspiring mission,” said Dr. Ratner. “Treating ovarian cancer is extremely challenging, as it is often resistant to treatment and has a high rate of recurrence. Eterna’s scientific data has been very impressive and shows a lot of promise. I’m eager to work closely with the team to advance ERNA-101 in ovarian cancer.”
James Bristol, Ph.D., chairman of the board at Eterna, commented, “Dr. Ratner is widely recognized as a trailblazer in ovarian cancer research and treatment, with a reputation for groundbreaking contributions that have advanced the field. Her unparalleled expertise and strategic insights will be invaluable as we continue to drive innovation and deliver transformative solutions for patients.”
